FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.
Age ≥ 18 years;
Patients diagnosed with TED;
Complete understanding and voluntary participation in this study, with the signing of an informed consent form.
Severe liver or kidney dysfunction;
Inability to maintain a supine position for 5 minutes to cooperate with the examination;
Suffering from claustrophobia or other psychiatric disorders;
Patients planning pregnancy or in the prenatal or lactation period;
Single group
18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT
Diagnostic testPatients underwent 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT scans within 10 days.
Diagnostic accuracy
The accuracy of 18F-AlF-FAPI PET/CT in assessing the activity of TED.
The value to predict therapy response
The changes of SUV metrics on 18F-AlF-FAPI PET/CT to predict therapy response
Diagnostic accuracy comparison
Comparing the diagnostic accuracy in assessing the activity of TED activity between 18F-AlF-FAPI PET/CT and 99mTc-DTPA SPECT/CT.
FAPI expression and SUV metrics
Correlation between SUV metrics on PET and FAPI expression in patients with surgery.
Click on the lead sponsor to view all of their trials.
